TACE for HCC by TANDEM and Idarubicin
Condition(s):Hepatocellular Carcinoma (HCC)Last Updated:April 25, 2018Completed
Hide Studies Not Open or Pending
Condition(s):Hepatocellular Carcinoma (HCC)Last Updated:April 25, 2018Completed
Condition(s):Acute Myeloid LeukemiaLast Updated:October 9, 2018Completed
Condition(s):Acute Myeloid LeukemiaLast Updated:July 28, 2015Completed
Condition(s):LeukemiaLast Updated:July 3, 2018Completed
Condition(s):Carcinoma, HepatocellularLast Updated:January 17, 2024Recruiting
Condition(s):Acute Myeloid LeukemiaLast Updated:September 8, 2023Recruiting
Condition(s):Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Refractory Anemia With Excess BlastsLast Updated:March 31, 2017Terminated
Condition(s):Acute Myelogenous LeukemiaLast Updated:September 29, 2010Completed
Condition(s):LeukemiaLast Updated:May 30, 2019Completed
Condition(s):Acute Myeloid Leukemia; Blasts 20 Percent or More of Bone Marrow Nucleated Cells; High Risk Myelodysplastic Syndrome; Recurrent Acute Biphenotypic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent High Risk Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory High Risk Myelodysplastic SyndromeLast Updated:November 30, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.